
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TTX-810
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Broad Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810
Details : TTX-810 is an IND-enabling candidate, a MCL1 inhibitor, a highly potent and selective macrocyclic compound to treat patients with solid tumor or hematological cancers.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 16, 2023
Lead Product(s) : TTX-810
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Broad Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
